↓ Skip to main content

Venous thromboembolism and lung cancer: a review

Overview of attention for article published in Multidisciplinary Respiratory Medicine, September 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#45 of 307)
  • High Attention Score compared to outputs of the same age (85th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

news
1 news outlet
twitter
1 X user

Citations

dimensions_citation
56 Dimensions

Readers on

mendeley
89 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Venous thromboembolism and lung cancer: a review
Published in
Multidisciplinary Respiratory Medicine, September 2015
DOI 10.1186/s40248-015-0021-4
Pubmed ID
Authors

Carolina Vitale, Maria D’Amato, Paolo Calabrò, Anna Agnese Stanziola, Mauro Mormile, Antonio Molino

Abstract

Venous thromboembolism (VTE) is a common complication of malignancies and epidemiological studies suggest that lung cancer belonged to the group of malignancies with the highest incidence rates of VTE. Risk factors for VTE in lung cancer patients are adenocarcinoma, NSCLC in comparison with SCLC, advanced disease, pneumonectomy, chemotherapy including antiangiogenic therapy. Other risk factors are pretreatment platelet counts and increased release of TF-positive microparticles. Elevated D-dimer levels do not necessarily indicate an increased risk of VTE but have been shown to be predictive for a worse clinical outcome in lung cancer patients. Mechanisms responsible for the increase in venous thrombosis in patients with lung cancer are not understood. Currently no biomarker is recognized as a predictor for VTE in lung cancer patients. Although several clinical trials have reported the efficacy of antithrombotic prophylaxis in patients with lung cancer who are receiving chemotherapy, further trials are needed to assess the clinical benefit since these patients are at an increased risk of developing a thromboembolism.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 89 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brunei Darussalam 1 1%
Unknown 88 99%

Demographic breakdown

Readers by professional status Count As %
Student > Postgraduate 14 16%
Researcher 10 11%
Student > Bachelor 9 10%
Student > Ph. D. Student 8 9%
Student > Master 8 9%
Other 18 20%
Unknown 22 25%
Readers by discipline Count As %
Medicine and Dentistry 45 51%
Biochemistry, Genetics and Molecular Biology 6 7%
Nursing and Health Professions 4 4%
Pharmacology, Toxicology and Pharmaceutical Science 4 4%
Immunology and Microbiology 2 2%
Other 5 6%
Unknown 23 26%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 March 2023.
All research outputs
#3,138,741
of 25,374,917 outputs
Outputs from Multidisciplinary Respiratory Medicine
#45
of 307 outputs
Outputs of similar age
#40,062
of 281,198 outputs
Outputs of similar age from Multidisciplinary Respiratory Medicine
#3
of 6 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 307 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.3. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 281,198 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.